Claims
- 1. A method of reducing and/or controlling excessive intraocular pressure in a host in need of such treatment comprising topically administering to said host an effective dose for lowering intraocular pressure of an ophthalmologically acceptable aminoalkoxyphenyl compound of the formula: ##STR74## in which: B represents a --S--, --SO-- or --SO.sub.2 -- group,
- R.sub.1 and R.sub.2, which are identical or different, each denote hydrogen, a methyl or ethyl radical or a halogen,
- A denotes a straight- or branched-alkylene radical having from 2 to 5 carbon atoms or a 2-hydroxypropylene radical in which the hydroxy is optionally substituted by a lower alkyl radical,
- R.sub.3 denotes an alkyl radical or a radical of formula
- --Alk--Ar
- in which Alk denotes a single bond or a linear- or branched-alkylene radical having from 1 to 5 carbon atoms and Ar denotes a pyridyl, phenyl, 2,3-methylenedioxyphenyl or 3,4-methylenedioxyphenyl radical or a phenyl group substituted with one or more substituents, which may be identical or different, selection from halogen atoms, lower alkyl groups or lower alkoxy groups,
- R.sub.4 denotes hydrogen or an alkyl radical, or R.sub.3 and R.sub.4 when taken together, denote an alkylene or alkenylene radical having from 3 to 6 carbon atoms and optionally substituted with a phenyl radical or optionally interrupted by --O--, --N.dbd. or --N--R.sub.11, R.sub.11 denoting hydrogen or a lower alkyl, phenyl, diphenylmethyl, benzyl or halogenbenzyl radical, and
- Cy represents an indolizinyl group.
- 2. A method according to claim 1 wherein Cy represents indolizin-3-yl.
- 3. A method according to claim 1 wherein the aminoalkoxyphenyl compound is administered to the human eye at a dose of about 5 ng to about 0.5 mg.
- 4. A method according to claim 3 wherein the aminoakoxyphenyl compound is administered to the human eye at a dose of about 5 ng to about 50 ng.
- 5. The method according to claim 1 wherein the aminoalkoxyphenyl compound is used in combination with an ophthalmologically acceptable carrier for topical use.
- 6. The method according to claim 1 wherein the aminoalkoxyphenyl compound is 2-isopropyl-1-[4-{3-[N-methyl-N-(3,4-dimethoxy-.beta.-phenethyl)amino]propyloxy}benzenesulphonyl]indolizine, its N-oxide derivative or a pharmaceutically acceptable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
86 02045 |
Feb 1986 |
FRX |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part application of co-pending application Ser. No. 082,554, filed Aug. 7, 1987, now U.S. Pat. No. 4,957,925 which is a continuation-in-part of application Ser. No. 006,233, filed Jan. 23, 1987, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3947470 |
Brenner et al. |
Mar 1976 |
|
4117128 |
Brenner |
Sep 1978 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0235111 |
Sep 1987 |
EPX |
2341578 |
Sep 1977 |
FRX |
2594438 |
Aug 1987 |
FRX |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
82554 |
Aug 1987 |
|
Parent |
6233 |
Jan 1987 |
|